pulmonary arterial hypertension

Cell-free hemoglobin in pulmonary hypertension

Cell-free hemoglobin generated by the lungs may be a therapeutic target for treating pulmonary arterial hypertension, Vanderbilt researchers found.

Study suggests new threshold for diagnosing PAH

Doctors diagnosing pulmonary arterial hypertension (PAH) — elevated pulmonary pressure due to an issue in the small vessels of the lung — rely on a hemodynamic threshold set in the early 1970s to determine whether patients would be candidates for pulmonary vasodilator therapy.

mitochondria dna image

Mitochondrial mutations and disease

New findings suggest that oxidative stress damages mitochondrial DNA, and they link this damage to a disease state.

Block estrogen to treat lung disease

Based on findings from Vanderbilt investigators and others, clinical trials of estrogen inhibition for pulmonary arterial hypertension have recently been approved and funded by the National Institutes of Health.

lungs

Marrow cells’ role in pulmonary hypertension explored

Cells from the bone marrow participate in the development of pulmonary arterial hypertension (PAH), and they can also protect against it, according to new findings from a team of Vanderbilt University Medical Center investigators.

Hypertension hiatus

New findings offer a potential strategy for preventing heritable pulmonary arterial hypertension.